Publication | Closed Access

Anti–programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study

Cancer ImmunosurveillanceOncologyAutoimmune DiseaseSystemic TreatmentImmune RegulationImmunologyClinical TrialsImmune Checkpoint InhibitorImmunotherapeuticsCancer PatientsImmunotherapyMedicinePre-existing Systemic Sclerosis